Karuna Therapeutics — Technical Presentation (August 2022)
21 slides from Karuna Therapeutics's technical presentation, Aug 8, 2022
Slide 1: Topline results: Phase 3 EMERGENT-2 trial of KarXT in schizophrenia
Topline results: Phase 3 EMERGENT-2 trial of KarXT in schizophrenia August 8, 2022 Exhibit 99.2
Slide 2: Forward looking statements
Forward looking statements This presentation and other related material may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding Karuna’s expectation about any or all of the following:
Slide 3: Agenda
Introduction Steve Paul, M.D. Chief Executive Officer, President, and Chairman of the Board Phase 3 EMERGENT-2 trial results Steve Brannan, M.D. Chief Medical Officer Next steps for KarXT Andrew Miller, Ph.D. Founder and Chief Operating Officer Closing remarks and Q&A Steve Paul, M.D. Andrew Miller,
Slide 4: Karuna means "compassion in action" in Sanskrit
Karuna means “compassion in action” in Sanskrit Our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions
Slide 5: KarXT (xanomeline-trospium): a novel M1/M4-preferring muscarinic agonist
KarXT (xanomeline-trospium): a novel m1/m4-preferring muscarinic agonist Sources: Brannan et al. 2021, Shekar et al. 2008, Bodick et al. 1997 Unique pharmacology enables potential use in complex mental illness Xanomeline stimulates both M1 & M4 receptors in the brain These receptors are expressed in
Slide 6: Need for new, differentiated treatments for schizophrenia
Need for new, differentiated treatments for schizophrenia Sources: GBD 2017, Patel et al. 2014, Remington et al. 2016, Goff et al. 2011, Liebermann et al. 2005 Chronic psychiatric condition affecting 21M+ people globally Schizophrenia is one of the leading causes of disability worldwide, with onset
Slide 7: Robust registrational program to support NDA submission requirements
Robust registrational program to support NDA submission requirements Submission of an NDA for KarXT in schizophrenia expected in mid-2023 NDA = New Drug Application; *Additional analysis ongoing EMERGENT-1 NCT03697252 EMERGENT-2 NCT04659161 EMERGENT-3 NCT04738123 EMERGENT-4 NCT04659174 EMERGENT-5 NC
Slide 8: Phase 3 EMERGENT-2 trial results
Phase 3 EMERGENT-2 trial results Steve Brannan, M.D. Chief Medical Officer
Slide 9: Phase 3 EMERGENT-2 trial design
Phase 3 EMERGENT-2 trial design KarXT dose is expressed as xanomeline/trospium (mg/mg) *Washout of prior oral lithium and/or antipsychotics; †Optional increase in dose based on tolerability determined by a clinician PANSS = Positive & Negative Syndrome Scale; CFB = change from baseline; BID = twice
Slide 10: Demographics and baseline characteristics
Demographics and baseline characteristics *Mean age represented in years; PANSS = Positive & Negative Syndrome Scale iTT population KarXT (n=126) Placebo (n=126) Mean age* 45.6 46.2 Sex, n (%) Male Female 95 (75.4) 31 (24.6) 95 (75.4) 31 (24.6) Race, n (%) Asian Black White Other 2 (1.6) 97 (77
Slide 11: Primary endpoint: PANSS total score at Week 5
Primary endpoint: PANSS total score at Week 5 All efficacy analyses performed using the modified intent-to-treat (mITT) analysis set, defined as all randomized participants who received at least one dose of study medication at baseline and at least one post-baseline PANSS assessment (KarXT n=117, pl
Slide 12: Secondary endpoint: PANSS positive subscale at Week 5
Secondary endpoint: PANSS positive subscale at Week 5 All efficacy analyses performed using the modified intent-to-treat (mITT) analysis set, defined as all randomized participants who received at least one dose of study medication and had a baseline and at least one post-baseline PANSS assessment (
Slide 13: Secondary endpoint: PANSS negative subscale at Week 5
Secondary endpoint: PANSS negative subscale at Week 5 All efficacy analyses performed using the modified intent-to-treat (mITT) analysis set, defined as all randomized participants who received at least one dose of study medication and had a baseline and at least one post-baseline PANSS assessment (
Slide 14: Secondary endpoint: PANSS negative Marder factor subscale at Week 5
Secondary endpoint: PANSS negative Marder factor subscale at Week 5 All efficacy analyses performed using the modified intent-to-treat (mITT) analysis set, defined as all randomized participants who received at least one dose of study medication at baseline and at least one post-baseline PANSS asses
Slide 15: Summary of safety and tolerability data
Summary of safety and tolerability data KarXT was generally well tolerated, with a side effect profile substantially consistent with prior trials Overall discontinuation rates were similar between KarXT and placebo groups (25% vs. 21%) Incidence rates of TEAEs were 75% (KarXT) and 58% (placebo) Disc
Slide 16: Next steps for KarXT
Next steps for KarXT Andrew Miller, Ph.D. Founder & Chief Operating Officer
Slide 17: Summary of EMERGENT-2 topline results
Summary of EMERGENT-2 topline results TEAE = treatment emergent adverse events; AEs = adverse events; EPS = extrapyramidal symptoms Clinically meaningful and statistically significant improvements in positive and negative symptoms of schizophrenia as measured by the primary and key secondary outcome
Slide 18: Robust Phase 3 EMERGENT clinical program to support NDA submission requirements
Robust Phase 3 EMERGENT clinical program to support NDA submission requirements NDA submission of KarXT in schizophrenia expected mid-2023 NDA = New Drug Application; NDA = New Drug Application *Additional analysis ongoing (EMERGENT-2) FDA has indicated EMERGENT-1, one successful Phase 3 efficacy an
Slide 19: Expanding KarXT's potential utility in psychiatry
Expanding KarXT’s potential utility in psychiatry *Additional analysis ongoing Five ongoing late-stage trials across large psychiatric conditions PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS / UPCOMING MILESTONE Schizophrenia Complete Schizophrenia Complete* Topline data Q1 2023 Enrolling Enro
Slide 20: Closing remarks and Q&A
Closing remarks and Q&A Steve Paul, M.D., Chief Executive Officer, President and Chairman of the Board Andrew Miller, Ph.D., Founder & Chief Operating Officer Troy Ignelzi, Chief Financial Officer
Slide 21: Thank you
Thank you |
Karuna Therapeutics — Technical Presentation (August 2022) on 6ix